Document:

Exhibit 10.1

 

AMENDMENT
NO. 3 TO AMENDED AND RESTATED UNSECURED TERM PROMISSORY NOTE

  

This
AMENDMENT No. 3 entered into this ____ day of November, 2017 (this “Amendment”) to the Amended and
Restated Unsecured Term Promissory Note effective September 1, 2015, issued by Myomo, Inc., a Delaware corporation (the “Maker”),
to Sandcastle Limited Partnership (the “Lender”), as amended by Amendment No. 1 to Amended and Restated Unsecured
Term Promissory Note on June 29, 2016 (“Amendment No. 1”) and Amendment No. 2 (“Amendment No. 2”)
to Amended and Restated Unsecured Term Promissory Note on May 23, 2017.

 

WHEREAS,
Maker issued to Steve Kelly on May 25, 2011 an Unsecured Term Convertible Promissory Note in the original stated principal
amount of $[______] (as amended prior to the effectiveness of the Restated Note (as defined below), the “Original Note”);

 

WHEREAS,
effective as of September 1, 2015, Maker and Lender amended and restated the Original Note in its entirety, in order to, among
other things, reflect the transfer by Steve Kelly of all rights, title and interest to Lender under the Original Note (the “Restated
Note”);

 

WHEREAS,
on June 29, 2016, the Maker and Lender amended the Restated Note pursuant to Amendment No. 1 to, among other things, modify the
repayment terms, provide for repayment in shares of the Maker’s capital stock in certain circumstances, and for subordination
of the Restated Note to certain other indebtedness of the Maker, all as provided for in Amendment No. 1.

 

WHEREAS,
on May 23, 2017, the Maker and Lender amended the Restated Note pursuant to Amendment No. 2 to, among other things, modify the
repayment terms, all as provided for in Amendment No. 2.

 

WHEREAS,
Maker and Lender now wish to further amend the Restated Note on the terms and conditions set forth herein, pursuant to Section
11 of the Restated Note, as amended to date.

 

WHEREAS,
Maker represents that it has the power and authority to enter into this Amendment and no consent of any other third party is required
for such entry by Maker.

 

NOW,
THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

 

1.           Effective Date. This Amendment shall be effective as of the date first set forth above.

 

     

     

    

 

2.           Payments.

 

a.          Section 1 of the Restated Note is deleted in its entirety and the following is inserted in lieu thereof:

 

The
outstanding balance shall bear interest at a rate of ten percent (10%) per annum, compounded annually based on a 365 day year,
until such time as there is no amount outstanding hereunder. Subject to Section 2 hereof, all outstanding amounts then due under
this Note shall be due and payable on June 8, 2019.

 

b.          Section 2 of the Restated Note is deleted in its entirety and the following is inserted in lieu thereof:

 

Notwithstanding
anything to the contrary, but subject to the last sentence of this Section 2, Maker may elect, in its sole discretion, to repay
up to fifty percent (50%) (rounded down to the nearest whole cent) of the aggregate outstanding amount (the principal amount and
all accrued but unpaid interest thereon) under this Note (such amount, the “Discounted Stock Repayment Amount”)
by issuing shares of Maker’s common stock, equal to the Discounted Stock Repayment Amount divided by that number equal to
80% of the closing price per share of Maker’s common stock quoted on the NYSE American (or another stock exchange or over-the-counter
dealer quotation system on which Maker’s common stock is then traded) on the date of such repayment. In addition, notwithstanding
anything to the contrary, but subject to the last sentence of this Section 2, Maker may elect, in its sole discretion, to repay
the remainder of the aggregate outstanding amount (the principal amount and all accrued but unpaid interest thereon) under this
Note that does not constitute the Discounted Stock Repayment Amount (the “Stock Repayment Amount”) by issuing
shares of Maker’s common stock, equal to the Stock Repayment Amount divided by that number equal to the closing price per
share of Maker’s common stock quoted on the NYSE American (or another stock exchange or over-the-counter dealer quotation
system on which Maker’s common stock is then traded) on the date of such repayment. Notwithstanding the foregoing, (i) in
no event shall Maker be required to, nor shall Maker, pursuant to this Section 2, issue shares of common stock or equity securities
convertible or exercisable for shares of common stock to the extent that such issuance would require shareholder approval pursuant
to Section 312.03 of the Listed Company Manual, (ii) Maker shall be permitted to make such election to repay the Discounted Stock
Repayment Amount and/or the Stock Repayment Amount in shares of common stock as provided in this Section 2 no later than 90 days
following the closing of Maker’s next offering of equity or equity-linked securities in which Maker receives gross proceeds
of at least $2,000,000, pursuant to an effective registration statement under the Securities Act of 1933, as amended, or a private
placement of such securities, in each case on or after November 8, 2017; and (iii) Maker shall be permitted to make such election
to repay the Discounted Stock Repayment Amount and/or the Stock Repayment Amount in shares of common stock as provided in this
Section 2 if and only if Maker’s common stock is then traded on the NYSE American (or another stock exchange or over-the-counter
dealer quotation system) on the date of such repayment.

 

3.           In accordance with Section 3 of the Note, pursuant to which, among other things, the amounts outstanding under the Note and Maker’s
obligations to the Lender are subordinated to certain other indebtedness of Maker, including that issued pursuant to the Accelerator
Funding Agreement, dated July 7, 2011, between the Company and the Massachusetts Life Sciences Center, as amended (the “MLSC
Loan”), Maker and the Lender agree, for the avoidance of doubt, that nothing contained in the Note shall require Maker
to repay any amounts outstanding or due under the Note in cash so long as the MLSC Loan is outstanding or Maker is otherwise prohibited
from doing so under the MLSC Loan, including pursuant to Section 4.2(f) thereof.

 

4.           Amendment Provision. This Amendment is entered into by Maker and Lender in a manner consistent with the provisions of Section
11 of the Restated Note. Except as expressly set forth in this Amendment, the Restated Note is not amended or modified, Lender
has not waived the terms of any of the Restated Note, and the terms and conditions of the Restated Note are ratified and confirmed
and such terms shall remain in full force and effect.

 

5.           General. Capitalized terms used herein and not defined shall have the meanings ascribed to them in the Restated Note. This
Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. The terms of this Amendment shall be construed in accordance with the laws of the Commonwealth
of Massachusetts, without regard to choice of law provisions.

 

    	 	2	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Amendment on the date first written above.

 

	LENDER:	 	MAKER:
	SANDCASTLE LIMITED PARTNERSHIP            	 	MYOMO, INC.

	 	 	 	 	 
	By:	 	 	By:	      
	Name:	             	 	 	Paul R. Gudonis
	Title:	 	 	 	Chief Executive Officer

 

 

3Exhibit 4.14

 

November 13, 2017

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

 

Re: UTStarcom Holdings Crop.

 

We have read the comments made by UTStarcom Holdings Corp. in Item 16F of this Form 20-F under the caption “Disengagement of GHP Horwath, P.C.” of Item 16F. We agree with such statements made regarding our firm. We have no basis to agree or disagree with other statements made in Item 16F of this Form 20-F.

 

Additionally, the Form 20-F discloses that UTStarcom Holdings Corp. restated its consolidated financial statements as of and for the year ended December 31, 2015. We have not been provided complete information requested of UTStarcom Holdings Corp. that would allow us to substantiate matters related to the restatement.

 

/s/ GHP Horwath, P.C.

Denver, Colorado

 

cc:  Mr. Sean Shao

Audit Committee Chairman

UTStarcom Holdings Corp.Exhibit 4.15

 

November 14, 2017

 

Office of the Chief Accountant

Securities and Exchange Commission

100 F Street, N. E.

Washington, D.C. 20549

 

Ladies and Gentlemen:

 

We have read the comments made regarding Crowe Horwath LLP in Item 16F of Form 20-F of UTStarcom Holdings Corp. dated November 14, 2017, as contained in the second and third paragraphs under the caption “Dismissal of Crowe Horwath LLP” of Item 16F, and are in agreement with those statements.

 

/s/ Crowe Horwath LLP

Denver, Colorado

 

cc: Mr. Sean Shao

Audit Committee Chairman

UTStarcom Holdings Corp.Exhibit
10.46

 

Promotion
Agreement

 

August
14, 2017

 

James B. Boyd

Address: [redacted]

 

Dear
Jim,

 

I
am pleased to offer you the full-time position of President and CFO with Marrone Bio Innovations, Inc. (the “Company”),
reporting to Pam Marrone, CEO. We anticipate your start date to be on August 15, 2017.

 

You
will receive an annual salary of $285,000. This represents a raise of $35,000 from your salary in your current role as CFO. Your
salary increase raise will be deferred until the Company completes a contemplated financial transaction. At that time you will
be paid an amount equal to the difference between your current salary and your new salary that you would have received between
your start date in your new role and the date that the deferral is completed. This position is considered by the Company to be
exempt under applicable federal and state law. Direct deposit of paychecks to your bank account is available.

 

Subject
to the approval of our Board of Directors and/or Compensation Committee of the Board, you will be granted 150,000 Restricted Stock
Units (“RSU’s”) of the Company’s common stock. The RSU’s will be granted on the date that you begin
your new position and will vest over a period of 3 years from the grant date. At the time of the grant of the RSU’s, the
Company will gross up your compensation to cover payment of the payroll taxes that you are required to pay on the RSU grant.

 

You
will continue to be eligible to participate in the Company Bonus Plan, which changes from year to year, must be approved by the
Board of Directors, and is based on Company and individual goals. The determination of the Company with respect to the amount
of bonus earned, if any, will be final and binding. Your bonus can be up to 40% of your salary.

 

You
will be continue to eligible for the Company’s benefits programs. The benefits currently offered are as follows:

 

	●	Medical
    (MBI offers you a choice of a PPO or HMO Plan), Dental and Vision Insurance for you. The Company will pay for 50% of your
    dependent premium for medical and dental insurance and you may pay the remaining 50% on a pre-tax basis under the Company’s
    medical plan.
	 	 
	●	Cafeteria
    Plan (Section 125 Plan) which gives you the ability to set aside a portion of your paycheck
    on a pre-tax basis for dependent premiums as well as set up a flexible spending account for dependent care and unreimbursed
    medical expenses. 

 

    	 	 	 

    	 

    

 

	●	Long-term
    Disability Insurance for you, and Life Insurance equal to one (1) times your base salary. 
	 	 
	●	Voluntary
    Supplemental Term Life Insurance and AD&D.

 

You
will continue to be eligible to participate in the 401(k) Plan after completing one month of service. Subject to terms of the
Plan, you will receive a Company match of $1 for $1 for the first 3% of your salary you contribute and $0.50 for the next 2% of
your salary (i.e. the maximum match is 4% if you contribute 5% of your salary).

 

You
will continue to accrue 4.62 hours of vacation per pay period, which is equivalent to 120 hours on an annual basis.

 

All
the benefit programs and plans are offered solely at the discretion of the Company and may

be
modified at any time. In addition to a timely response, this offer is contingent upon successfully passing (1) a background check,
which may include work references, criminal, and education credential checks and (2) a pre-employment drug test. For purposes
of federal immigration laws, you are required to provide to the Company documentary evidence of your identity and eligibility
to work in the United States. Such documentation must be provided to us within three (3) business days of your date of hire or
our contingent employment relationship with you will be terminated. You will also be required, as a condition of employment, to
sign the Company’s standard Employee Confidential Information and Assignment of Inventions Agreement.

 

To
indicate your acceptance of the Company’s offer, please sign and date this letter in the space provided below and return
it to Human Resources. This letter sets forth the terms of your employment with the Company and supersedes any prior representations
or agreements, whether written or oral. This letter may not be modified or amended except by a written agreement signed by the
Company and by you.

 

Please
respond no later than August 15, 2017. If we do not receive your acceptance by that time, we will assume you are not interested
and this offer will be automatically withdrawn without further action.

 

Your
employment with the Company is for no specified period and constitutes at-will employment. As a result, you are free to resign
at any time, for any reason or for no reason. We prefer that if you resign you would provide a two-week notice. Similarly, the
Company is free to conclude its employment relationship with you at any time, with or without cause.

 

I
look forward to continuing to build MBI together with you.

 

    	 	 	 

    	 

    

 

Sincerely,

 

	/s/
    Linda Moore	 
	Linda
    V. Moore	 
	SVP
    and General Counsel	 

 

I,
James B. Boyd, accept the terms of this agreement.

 

	Signature:	/s/
    James     B. Boyd 	 
	 	 	 
	Date
    Signed: 	8/15/2017

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}]]